Generic Rulide ( Roxithromycin )

Buy Generic Rulide (Roxithromycin) without prescription in Canada

In our Canadian pharmacy, you can buy Rulide (Roxithromycin) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Rulide (roxithromycin) is a semi‑synthetic macrolide antibiotic structurally related to erythromycin. It is used to treat a variety of mild to moderate bacterial infections of the respiratory tract, skin and soft tissues, and urogenital tract caused by susceptible organisms. Roxithromycin works by binding to the 50S ribosomal subunit of bacteria, inhibiting the translocation of peptides during protein synthesis and thereby preventing bacterial growth. It is predominantly bacteriostatic but can be bactericidal at higher concentrations against highly sensitive organisms.

Usual adult dose: The recommended dose is 150 mg taken orally twice daily, approximately every 12 hours, or 300 mg once daily depending on the severity and type of infection. For most respiratory and skin infections, a twice‑daily regimen is preferred. The tablets should be swallowed whole with a glass of water and should be taken at least 15 minutes before meals, as food significantly reduces absorption. The duration of therapy is typically 5 to 10 days, depending on the infection and clinical response. For streptococcal infections, a minimum of 10 days of therapy is recommended to prevent rheumatic fever.

Dosage form: Film‑coated oral tablets, 150 mg. A 300 mg tablet is also available in some international markets.

Onset of action: Roxithromycin is rapidly absorbed, with peak plasma concentrations reached approximately 1.5 to 2 hours after an oral dose on an empty stomach. Clinical improvement, such as reduction of fever and symptoms, is usually observed within 48 to 72 hours of starting therapy, though the full course must be completed to ensure bacterial eradication.

Duration of action: The elimination half‑life of roxithromycin is approximately 10 to 12 hours, which supports twice‑daily dosing. Therapeutic concentrations in tissues and plasma are maintained above the minimum inhibitory concentration (MIC) for susceptible organisms throughout the dosing interval when taken as prescribed.

Alcohol recommendation: Alcohol consumption does not have a direct pharmacokinetic interaction with Rulide, but it should be limited or avoided during treatment. Alcohol can worsen gastrointestinal side effects such as nausea and diarrhoea, impair the body’s immune response, and contribute to dehydration. Heavy alcohol intake may also place additional strain on the liver.

Most common side effects: Nausea, vomiting, abdominal pain, diarrhoea, and flatulence. Other common effects include headache, dizziness, and skin rash. Macrolides are known to prolong the QT interval in susceptible individuals, increasing the risk of cardiac arrhythmias. Rare but serious adverse effects include hepatotoxicity (cholestatic hepatitis), severe hypersensitivity reactions (including angioedema and anaphylaxis), Clostridioides difficile‑associated diarrhoea, and, rarely, pancreatitis.

Would you like to try Rulide (Roxithromycin) without a prescription?

General Information about Rulide (Roxithromycin)

• INN (International Nonproprietary Name): Roxithromycin
• Brand names available in Canada: Rulide® is not marketed in Canada. Roxithromycin is not approved by Health Canada for sale. It is, however, widely available in many other countries, including Australia, France, and several European and Asian nations under the brand name Rulide and generic roxithromycin tablets. Our pharmacy supplies internationally sourced Rulide through the international supply chain for personal importation.
• ATC code: J01FA06 (roxithromycin; macrolides, lincosamides and streptogramins).
• Dosage forms and strengths: Film‑coated oral tablets: 150 mg and 300 mg.
• Manufacturers in Canada: None. Roxithromycin is not manufactured in Canada. The original brand is manufactured by Sanofi‑Aventis in various international markets. Generic roxithromycin is produced by several international pharmaceutical companies. Our pharmacy obtains the medication through the international supply chain for personal use.
• Registration status in Canada: Not marketed in Canada. Rulide has not been issued a Notice of Compliance by Health Canada and is not listed in the Drug Product Database. It is, however, approved by regulatory authorities in other countries, including the Therapeutic Goods Administration (TGA) in Australia and the European Medicines Agency (EMA).
• OTC / Rx classification: Prescription only (Rx). A valid prescription from a licensed Canadian healthcare professional is required. Our pharmacy fulfills this prescription for the internationally sourced product.

Mechanism of Action and Pharmacology

Roxithromycin is a semi‑synthetic derivative of erythromycin belonging to the macrolide class. It exerts its antibacterial effect by binding to the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome, thereby blocking the translocation of peptidyl‑tRNA and inhibiting protein synthesis. Roxithromycin is mainly bacteriostatic but can be bactericidal in high concentrations against highly sensitive organisms. Its spectrum of activity includes Gram‑positive aerobes such as Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus (methicillin‑susceptible), and Corynebacterium diphtheriae; Gram‑negative organisms such as Haemophilus influenzae, Moraxella catarrhalis, and Neisseria gonorrhoeae; atypical bacteria including Mycoplasma pneumoniae, Chlamydia trachomatis, Chlamydophila pneumoniae, and Legionella pneumophila; and some anaerobic organisms. It has improved acid stability and a longer elimination half‑life compared with erythromycin, allowing for twice‑daily or once‑daily dosing.

After oral administration, roxithromycin is rapidly absorbed. The absolute bioavailability is approximately 50% when taken on an empty stomach; food significantly decreases the rate and extent of absorption, so the tablets should be taken at least 15 minutes before meals. Peak plasma concentrations are achieved within 1.5 to 2 hours of a dose. Roxithromycin is highly lipid‑soluble and penetrates well into tissues, including the lung, tonsils, prostate, and middle ear fluid, achieving tissue concentrations higher than concurrent plasma concentrations. It is approximately 96% bound to plasma proteins. Roxithromycin is partially metabolised in the liver, primarily by CYP3A4, to inactive descladinose and N‑demethyl metabolites. The elimination half‑life is 10 to 12 hours, permitting twice‑daily administration. The drug is excreted mainly in the faeces (53%) and urine (7% as unchanged drug).

Indications

• Upper respiratory tract infections: pharyngitis, tonsillitis, acute sinusitis, and acute otitis media caused by susceptible organisms.
• Lower respiratory tract infections: acute exacerbations of chronic bronchitis, community‑acquired pneumonia (mild to moderate) caused by typical and atypical pathogens.
• Uncomplicated skin and soft tissue infections: cellulitis, impetigo, erysipelas, and folliculitis caused by susceptible staphylococci and streptococci.
• Urogenital infections: non‑gonococcal urethritis and cervicitis caused by Chlamydia trachomatis and Ureaplasma urealyticum. Roxithromycin is also used as an alternative in the treatment of early syphilis in penicillin‑allergic patients.
• Lyme disease (early stages) as an alternative for patients intolerant of first‑line agents.
• Prophylaxis against rheumatic fever and endocarditis in penicillin‑allergic patients (off‑label).

Important Warnings and Precautions

At‑risk groups

• Pregnancy: There are limited data on the use of roxithromycin during pregnancy. Animal studies have not demonstrated teratogenic effects, but safety in human pregnancy has not been firmly established. Roxithromycin should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the foetus. Women of childbearing potential should inform their physician if they become pregnant during therapy.
• Breastfeeding: Roxithromycin is excreted in human breast milk in small amounts. A decision must be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother. The nursing infant should be monitored for gastrointestinal disturbances such as diarrhoea, candidiasis, or allergic sensitization.
• Paediatrics: Roxithromycin is not typically recommended for children under 12 years of age for the tablet formulation. Paediatric dosing is weight‑based and is usually given as a suspension; safety and efficacy in children have not been established for the 150 mg tablet. Use in children should be under specialist guidance.
• Elderly: No specific dose adjustment is required based on age alone. However, elderly patients are more likely to have age‑related renal or hepatic impairment, and they may be at increased risk of QT prolongation and arrhythmias. Renal and hepatic function should be assessed before and during therapy.
• Hepatic impairment: Roxithromycin is metabolised in the liver. It should be used with caution in patients with impaired hepatic function. Liver function tests should be monitored periodically during treatment. Roxithromycin is contraindicated in patients with severe hepatic impairment and in those with a history of cholestatic jaundice or hepatic dysfunction associated with previous macrolide use.
• Renal impairment: No significant accumulation occurs in patients with renal insufficiency because roxithromycin is primarily excreted via the faeces and hepatic metabolism. No dose adjustment is required for patients with mild to moderate renal impairment. In patients with severe renal failure, roxithromycin should be used with caution, as data are limited.
• QT prolongation: Macrolide antibiotics, including roxithromycin, can prolong cardiac repolarisation and the QT interval, imparting a risk of developing cardiac arrhythmia and torsade de pointes. Prescribers should weigh the risks and benefits. Risk factors include a history of torsade de pointes, congenital or documented QT prolongation, concomitant use of drugs known to prolong the QT interval (antiarrhythmics of classes IA and III, antipsychotic agents, antidepressants, and fluoroquinolones), electrolyte disturbance (particularly hypokalaemia and hypomagnesaemia), clinically relevant bradycardia, cardiac arrhythmia, cardiac insufficiency, and advanced age. ECG monitoring is recommended in at‑risk patients.
• Clostridioides difficile‑associated diarrhoea (CDAD): As with nearly all systemic antibacterial agents, CDAD has been reported with roxithromycin and may range from mild diarrhoea to fatal pseudomembranous colitis. CDAD should be considered in any patient who develops diarrhoea during or up to 2 months after antibiotic therapy. Anti‑motility agents should be avoided if CDAD is suspected.
• Myasthenia gravis: Macrolides may aggravate muscle weakness in patients with myasthenia gravis. Use with caution, and monitor for worsening of symptoms.
• Hypersensitivity: Serious and sometimes fatal allergic reactions, including angioedema, anaphylaxis, and severe cutaneous adverse reactions such as Stevens‑Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported with macrolides. If an allergic reaction occurs, the drug should be discontinued immediately and appropriate therapy instituted. Physicians should be aware that reappearance of allergic symptoms may occur when symptomatic therapy is discontinued.
• Allergy: Do not take Rulide if you have a known hypersensitivity to roxithromycin, erythromycin, or any other macrolide antibiotic, or to any excipient in the tablet formulation.

Driving and alcohol

Rulide is not generally expected to impair the ability to drive or operate machinery. However, some patients may experience dizziness, headache, or visual disturbances. Patients should be cautious when driving or performing hazardous tasks until they know how the medication affects them. Alcohol consumption should be limited during treatment. While there is no direct disulfiram‑like interaction, alcohol can worsen gastrointestinal side effects such as nausea and diarrhoea, impair the immune response, and increase the risk of hepatotoxicity, particularly in patients with pre‑existing liver disease.

Dosage Instructions

• Standard adult dose (≥ 40 kg): 150 mg taken orally twice daily, approximately every 12 hours, or 300 mg once daily, depending on the type and severity of infection. For most respiratory and skin infections, twice‑daily dosing is recommended to maintain optimal tissue concentrations.
• Streptococcal pharyngitis/tonsillitis: 150 mg twice daily for at least 10 days to prevent acute rheumatic fever.
• Urogenital chlamydial infections: 150 mg twice daily for 10‑14 days, or as directed by a specialist.
• Elderly patients and patients weighing less than 40 kg: The recommended dose is 150 mg once daily, or 150 mg twice daily under close monitoring, depending on the severity of infection and renal/hepatic function.
• Administration: The tablets must be taken on an empty stomach, at least 15 minutes before a meal, to ensure adequate absorption. Swallow the tablet whole with a glass of water; do not crush or chew. Space doses evenly (every 12 hours). Complete the full prescribed course of therapy, even if symptoms improve earlier.
• Missed dose: If a dose is missed, take it as soon as remembered on an empty stomach. If it is close to the time of the next scheduled dose, skip the missed dose and continue with the regular schedule. Do not double the dose.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Nausea, vomiting, and epigastric pain. These gastrointestinal effects are generally mild and dose‑dependent.
• Common side effects (1‑10%): Diarrhoea, flatulence, headache, dizziness, and skin rash.
• Uncommon but serious side effects: QT interval prolongation and torsade de pointes (may be fatal). Hepatotoxicity, including cholestatic hepatitis and hepatic failure (rare but sometimes fatal). Severe allergic reactions including angioedema, anaphylaxis, Stevens‑Johnson syndrome, and toxic epidermal necrolysis. Clostridioides difficile‑associated diarrhoea (may be severe). Pancreatitis (rare). Disturbances of taste and/or smell (usually reversible).
• Contraindications: Known hypersensitivity to roxithromycin, erythromycin, any macrolide or ketolide antibacterial agent, or any excipient in the tablet. History of cholestatic jaundice or hepatic dysfunction associated with prior macrolide use. Concomitant use with ergot derivatives (ergotamine, dihydroergotamine). Severe hepatic impairment.

Drug Interactions

• Ergot derivatives — contraindicated: Co‑administration may precipitate acute ergot toxicity characterised by severe peripheral vasospasm, dysesthesia, and possible central nervous system effects. This combination should be avoided.
• QT‑prolonging drugs — major interaction (avoid or monitor closely): Concomitant use with other drugs that prolong the QT interval—such as Class IA and III antiarrhythmics (quinidine, procainamide, dofetilide, amiodarone, sotalol), antipsychotics, tricyclic antidepressants, and fluoroquinolones—significantly increases the risk of torsade de pointes and cardiac arrest. These combinations should be avoided when possible; if unavoidable, ECG monitoring is recommended.
• Warfarin — moderate interaction: Roxithromycin may potentiate the anticoagulant effect of warfarin. Close monitoring of the International Normalised Ratio (INR) is recommended during and for several days after concurrent therapy.
• Theophylline — moderate interaction: Roxithromycin may modestly increase theophylline serum concentrations. Monitoring of serum theophylline levels is recommended when co‑administered.
• Cisapride, pimozide — contraindicated: Like other macrolides, roxithromycin should not be co‑administered with these drugs due to the risk of QT prolongation and life‑threatening arrhythmias.
• Midazolam — moderate interaction: Roxithromycin may increase the plasma concentration and sedative effects of midazolam. Dosage reduction of midazolam may be necessary.
• Disopyramide — moderate interaction: Roxithromycin may increase disopyramide plasma levels, requiring monitoring.
• Digoxin — moderate interaction: Macrolides may increase the absorption and serum concentrations of digoxin by inhibiting P‑glycoprotein, potentially leading to digoxin toxicity. Serum digoxin levels should be monitored.
• Oral contraceptives: As with other antibiotics, roxithromycin may transiently reduce the efficacy of combined oral contraceptives. A backup barrier method is recommended during treatment and for at least 7 days after completing the course.

Practical Advice

• Administration: Take Rulide on an empty stomach, at least 15 minutes before a meal, with a full glass of water. This ensures optimal absorption. Do not take with food or milk, as this significantly reduces the amount of drug absorbed. Space your doses evenly (e.g., 8:00 a.m. and 8:00 p.m.). Complete the full course of therapy.
• Monitoring: No routine laboratory monitoring is required for healthy individuals on short‑term therapy. In patients with pre‑existing liver disease, monitor liver function tests periodically. For those at risk of QT prolongation, an ECG should be considered before and during treatment. Patients on warfarin should have their INR checked more frequently.
• Storage: Store at room temperature (15‑30 °C) in a dry place, protected from moisture and light. Keep the container tightly closed. Keep out of the reach and sight of children.
• Lifestyle: Drink plenty of fluids to stay hydrated. Avoid alcohol to minimise gastrointestinal upset and liver strain. If diarrhoea develops, especially if watery or bloody, contact your doctor before taking anti‑diarrhoeal medication. Inform any healthcare professional that you are taking Rulide, particularly if you are scheduled for surgery or require any new medications.
• When to seek medical review: Contact your doctor immediately if you develop signs of an allergic reaction (rash, hives, itching, swelling of the face, lips, or tongue, difficulty breathing), signs of liver injury (yellowing of the skin or eyes, dark urine, right upper abdominal pain, severe fatigue), severe or bloody diarrhoea, palpitations, fainting, or a rapid, irregular heartbeat.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Azithromycin (Zithromax®) and clarithromycin (Biaxin®): Other macrolide antibiotics with a similar spectrum of activity. Azithromycin has a longer half‑life, allowing shorter courses, while clarithromycin is dosed twice daily. Both are available in Canada.
• Erythromycin: The original macrolide, though less well tolerated due to gastrointestinal side effects and a higher potential for drug interactions.
• Amoxicillin (Amoxil®) or amoxicillin‑clavulanate (Clavulin®): Penicillin‑based antibiotics that are first‑line for many respiratory and skin infections. They are generally well tolerated and have a different safety profile.
• Cefuroxime axetil (Ceftin®): A second‑generation cephalosporin alternative for respiratory and skin infections, particularly when beta‑lactamase‑producing organisms are suspected.
• Doxycycline (Vibramycin®): A tetracycline antibiotic that covers many respiratory pathogens and is first‑line for atypical pneumonia and chlamydial infections. An alternative for penicillin‑allergic patients.
• Fluoroquinolones (e.g., levofloxacin, moxifloxacin): Reserved for more severe infections or when first‑line agents are not suitable, due to their side‑effect profile.

Clinical Efficacy

Roxithromycin has been evaluated in numerous clinical trials for a variety of community‑acquired infections. In the treatment of community‑acquired pneumonia, roxithromycin 150 mg twice daily demonstrated clinical success rates of 85‑95%, comparable to clarithromycin and erythromycin, with better gastrointestinal tolerability. For streptococcal pharyngitis, a 10‑day course achieves bacteriological eradication rates exceeding 85%, although it is not the first‑line agent (penicillin remains the drug of choice). In urogenital chlamydial infections, roxithromycin is highly effective, achieving cure rates of over 90% with a 10‑ to 14‑day course. For skin and soft tissue infections, it is comparable to other macrolides and older penicillins. The drug’s improved acid stability, longer half‑life (allowing twice‑daily dosing), and better gastrointestinal tolerance give it an advantage over erythromycin. However, macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes is a growing global concern, and roxithromycin is not a first‑line agent for respiratory infections in Canada, where other antibiotics (amoxicillin, doxycycline, respiratory fluoroquinolones) are preferred based on local resistance patterns. As roxithromycin is not approved in Canada, its use is reserved for situations where the patient has a specific indication and other approved agents are not suitable, with the understanding that it is imported under a valid prescription.

Important:

Rulide (roxithromycin) is a prescription antibiotic that must be used under the supervision of a qualified healthcare professional. It is not approved for marketing in Canada and is imported for personal use under a valid prescription. This medication can cause a change in the electrical activity of the heart (QT prolongation), which can lead to serious (rarely fatal) fast/irregular heartbeat and other symptoms, such as severe dizziness and fainting, requiring immediate medical attention. The risk is increased in elderly patients, those with a history of heart rhythm problems, and those taking other QT‑prolonging medications. Serious and potentially fatal liver injury has been reported; discontinue Rulide immediately and contact your doctor if you develop signs of hepatitis (jaundice, dark urine, right upper abdominal pain, unexplained fatigue). Allergic reactions, including severe skin reactions, can occur. If you experience a rash, hives, difficulty breathing, or swelling of the face, lips, tongue, or throat, stop taking the medication and seek emergency medical attention. Rulide is contraindicated in patients with a history of liver dysfunction associated with macrolide use. This medication must be taken on an empty stomach at least 15 minutes before a meal for proper absorption. Do not take this medication with ergotamine or dihydroergotamine (used to treat migraines). This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Rulide - Shipping across Canada